Aurobindo Pharma gets US FDA nod for valganciclovir tabs

By: |
April 01, 2016 3:28 PM

Valganciclovir tablets is an anti-viral used in the treatment of Cytomegalovirus (CMV) retinitis Aurobindo Pharma received final approval from the US Food & Drug Administration (US FDA) to manufacture and market valganciclovir tablets USP, 450 mg. This product is to be launched in Q1 FY16-17. The approved ANDA is bioequivalent and therapeutically equivalent to the […]

Valganciclovir tablets is an anti-viral used in the treatment of Cytomegalovirus (CMV) retinitis

Aurobindo Pharma received final approval from the US Food & Drug Administration (US FDA) to manufacture and market valganciclovir tablets USP, 450 mg. This product is to be launched in Q1 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Valcyte of Hoffman-La Roche Inc.

Valganciclovir tablets is an anti-viral used in the treatment of Cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome and prevention of CMV disease in kidney, heart or kidney-pancreas transplant patients. According to IMS, the approved product has an estimated market size of US $ 391 million for the 12 months ending February 2016.

This is the 69th ANDA (including 15 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products. Aurobindo now has a total of 251 ANDA approvals (215 Final approvals including 10 from Aurolife Pharma LLC and 36 tentative approvals) from US FDA.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.